A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen
Comparative analyses of SARS-CoV-2-specific immune responses elicited by diverse prime-boost regimens are required to establish efficient regimens for the control of COVID-19. In this prospective observational cohort study, spike-specific immunoglobulin G (IgG) and neutralizing antibodies (nAbs) alo...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2023-03, Vol.41 (10), p.1694-1702 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1702 |
|---|---|
| container_issue | 10 |
| container_start_page | 1694 |
| container_title | Vaccine |
| container_volume | 41 |
| creator | Baek, Yae Jee Kim, Woo-Joong Ko, Jae-Hoon Lee, Youn-Jung Ahn, Jin Young Kim, Jung Ho Jang, Ho Cheol Jeong, Hye Won Kim, Yong Chan Park, Yoon Soo Kim, Sung-Han Peck, Kyong Ran Shin, Eui-Cheol Choi, Jun Yong |
| description | Comparative analyses of SARS-CoV-2-specific immune responses elicited by diverse prime-boost regimens are required to establish efficient regimens for the control of COVID-19.
In this prospective observational cohort study, spike-specific immunoglobulin G (IgG) and neutralizing antibodies (nAbs) alongside spike-specific T-cell responses in age-matched groups of homologous BNT162b2/BNT162b2 or AZD1222/AZD1222 vaccination, heterologous AZD1222/BNT162b2 vaccination, and prior wild-type SARS-CoV-2 infection/vaccination were evaluated.
Peak immune responses were achieved after the second vaccine dose in the naïve vaccinated groups and after the first dose in the prior infection/vaccination group. Peak titers of anti-spike IgG and nAb were significantly higher in the AZD1222/BNT162b2 vaccination and prior infection/vaccination groups than in the BNT162b2/BNT162b2 or AZD1222/AZD1222 groups. However, the frequency of interferon-γ-producing CD4+ T cells was highest in the BNT162b2/BNT162b2 vaccination group. Similar results were observed in the analysis of polyfunctional T cells. When nAb and CD4+T-cell responses against the Delta variant were analyzed, the prior infection/vaccination group exhibited higher responses than the groups of other homologous or heterologous vaccination regimens.
nAbs are efficiently elicited by heterologous AZD1222/BNT162b2 vaccination, as well as prior infection/vaccination, whereas spike-specific CD4+T-cell responses are efficiently elicited by homologous BNT162b2 vaccination. Variant-recognizing immunity is more efficiently generated by prior infection/vaccination than the other homologous or heterologous vaccination regimens. |
| doi_str_mv | 10.1016/j.vaccine.2023.01.063 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9901539</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X23000944</els_id><sourcerecordid>2780405193</sourcerecordid><originalsourceid>FETCH-LOGICAL-c495t-2c1550f98859bd0b3d43e8f2911b671ee4b5aee546b33314cd48c85c1ff165783</originalsourceid><addsrcrecordid>eNqFUk2P0zAQjRCILQs_AWSJCwdS_JnEF1BZPqUVXIqEuFixM2ldJfau7VQqf4k_iaN2K-DCxbbGb97Mm3lF8ZTgJcGkerVb7ltjrIMlxZQtMVniit0rFqSpWUkFae4XC0wrXnKCv18Uj2LcYYwFI_JhccGqWvC64ovi1wptIUHwg9_4KaLVj3eEUopugh2t26DWdejtlzWpqKZIex_THA2wsSM4NPoACPreGgsuDQcEQ36miBxMKbSD_XnkSFb7zkJ8ifSUkPMJjZBzD2iNDAxDjqdt6_IBaOvHu17OdU_lHhcP-naI8OR0XxbfPrxfX30qr79-_Hy1ui4NlyKV1BAhcC-bRkjdYc06zqDpqSREVzUB4Fq0AIJXmjFGuOl4YxphSN-TStQNuyxeH3lvJj1CZ7K0rEXNI2nDQfnWqr9_nN2qjd8rKTERTGaCFyeC4G8niEmNNs5CWwdZmKJ1zRspJOYZ-vwf6M5PwWV5GdVgjgWRLKPEEWWCjzFAf26GYDXbQe3UyQ5qtoPCRGU75Lxnfyo5Z93tPwPeHAGQ57m3EFScV2mgswFMUp23_ynxG_Cyyms</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2780405193</pqid></control><display><type>article</type><title>A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Baek, Yae Jee ; Kim, Woo-Joong ; Ko, Jae-Hoon ; Lee, Youn-Jung ; Ahn, Jin Young ; Kim, Jung Ho ; Jang, Ho Cheol ; Jeong, Hye Won ; Kim, Yong Chan ; Park, Yoon Soo ; Kim, Sung-Han ; Peck, Kyong Ran ; Shin, Eui-Cheol ; Choi, Jun Yong</creator><creatorcontrib>Baek, Yae Jee ; Kim, Woo-Joong ; Ko, Jae-Hoon ; Lee, Youn-Jung ; Ahn, Jin Young ; Kim, Jung Ho ; Jang, Ho Cheol ; Jeong, Hye Won ; Kim, Yong Chan ; Park, Yoon Soo ; Kim, Sung-Han ; Peck, Kyong Ran ; Shin, Eui-Cheol ; Choi, Jun Yong</creatorcontrib><description>Comparative analyses of SARS-CoV-2-specific immune responses elicited by diverse prime-boost regimens are required to establish efficient regimens for the control of COVID-19.
In this prospective observational cohort study, spike-specific immunoglobulin G (IgG) and neutralizing antibodies (nAbs) alongside spike-specific T-cell responses in age-matched groups of homologous BNT162b2/BNT162b2 or AZD1222/AZD1222 vaccination, heterologous AZD1222/BNT162b2 vaccination, and prior wild-type SARS-CoV-2 infection/vaccination were evaluated.
Peak immune responses were achieved after the second vaccine dose in the naïve vaccinated groups and after the first dose in the prior infection/vaccination group. Peak titers of anti-spike IgG and nAb were significantly higher in the AZD1222/BNT162b2 vaccination and prior infection/vaccination groups than in the BNT162b2/BNT162b2 or AZD1222/AZD1222 groups. However, the frequency of interferon-γ-producing CD4+ T cells was highest in the BNT162b2/BNT162b2 vaccination group. Similar results were observed in the analysis of polyfunctional T cells. When nAb and CD4+T-cell responses against the Delta variant were analyzed, the prior infection/vaccination group exhibited higher responses than the groups of other homologous or heterologous vaccination regimens.
nAbs are efficiently elicited by heterologous AZD1222/BNT162b2 vaccination, as well as prior infection/vaccination, whereas spike-specific CD4+T-cell responses are efficiently elicited by homologous BNT162b2 vaccination. Variant-recognizing immunity is more efficiently generated by prior infection/vaccination than the other homologous or heterologous vaccination regimens.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2023.01.063</identifier><identifier>PMID: 36754764</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Age ; Antibodies ; Antibodies, Neutralizing ; Antibodies, Viral ; Antigens ; BNT162 Vaccine ; CD4 antigen ; ChAdOx1 nCoV-19 ; Comparative analysis ; Coronaviruses ; COVID-19 ; COVID-19 vaccines ; Demographics ; Disease transmission ; Heterologous vaccination ; Homology ; Humans ; Hybrid immunity ; IgG antibody ; Immunization ; Immunoassay ; Immunoglobulin G ; Immunologic Memory ; Immunological memory ; Infections ; Lymphocytes ; Lymphocytes T ; Medical personnel ; Memory cells ; Neutralizing ; Neutralizing antibody ; Observational studies ; Peptides ; Plasma ; Priming ; Prospective Studies ; Proteins ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; T cell ; T-Lymphocytes - immunology ; Tumor necrosis factor-TNF ; Vaccination ; Vaccine ; γ-Interferon</subject><ispartof>Vaccine, 2023-03, Vol.41 (10), p.1694-1702</ispartof><rights>2023 Elsevier Ltd</rights><rights>Copyright © 2023 Elsevier Ltd. All rights reserved.</rights><rights>2023. Elsevier Ltd</rights><rights>2023 Elsevier Ltd. All rights reserved. 2023 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c495t-2c1550f98859bd0b3d43e8f2911b671ee4b5aee546b33314cd48c85c1ff165783</citedby><cites>FETCH-LOGICAL-c495t-2c1550f98859bd0b3d43e8f2911b671ee4b5aee546b33314cd48c85c1ff165783</cites><orcidid>0000-0002-2490-2485 ; 0000-0002-6308-9503 ; 0000-0002-9490-6609</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X23000944$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36754764$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baek, Yae Jee</creatorcontrib><creatorcontrib>Kim, Woo-Joong</creatorcontrib><creatorcontrib>Ko, Jae-Hoon</creatorcontrib><creatorcontrib>Lee, Youn-Jung</creatorcontrib><creatorcontrib>Ahn, Jin Young</creatorcontrib><creatorcontrib>Kim, Jung Ho</creatorcontrib><creatorcontrib>Jang, Ho Cheol</creatorcontrib><creatorcontrib>Jeong, Hye Won</creatorcontrib><creatorcontrib>Kim, Yong Chan</creatorcontrib><creatorcontrib>Park, Yoon Soo</creatorcontrib><creatorcontrib>Kim, Sung-Han</creatorcontrib><creatorcontrib>Peck, Kyong Ran</creatorcontrib><creatorcontrib>Shin, Eui-Cheol</creatorcontrib><creatorcontrib>Choi, Jun Yong</creatorcontrib><title>A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Comparative analyses of SARS-CoV-2-specific immune responses elicited by diverse prime-boost regimens are required to establish efficient regimens for the control of COVID-19.
In this prospective observational cohort study, spike-specific immunoglobulin G (IgG) and neutralizing antibodies (nAbs) alongside spike-specific T-cell responses in age-matched groups of homologous BNT162b2/BNT162b2 or AZD1222/AZD1222 vaccination, heterologous AZD1222/BNT162b2 vaccination, and prior wild-type SARS-CoV-2 infection/vaccination were evaluated.
Peak immune responses were achieved after the second vaccine dose in the naïve vaccinated groups and after the first dose in the prior infection/vaccination group. Peak titers of anti-spike IgG and nAb were significantly higher in the AZD1222/BNT162b2 vaccination and prior infection/vaccination groups than in the BNT162b2/BNT162b2 or AZD1222/AZD1222 groups. However, the frequency of interferon-γ-producing CD4+ T cells was highest in the BNT162b2/BNT162b2 vaccination group. Similar results were observed in the analysis of polyfunctional T cells. When nAb and CD4+T-cell responses against the Delta variant were analyzed, the prior infection/vaccination group exhibited higher responses than the groups of other homologous or heterologous vaccination regimens.
nAbs are efficiently elicited by heterologous AZD1222/BNT162b2 vaccination, as well as prior infection/vaccination, whereas spike-specific CD4+T-cell responses are efficiently elicited by homologous BNT162b2 vaccination. Variant-recognizing immunity is more efficiently generated by prior infection/vaccination than the other homologous or heterologous vaccination regimens.</description><subject>Age</subject><subject>Antibodies</subject><subject>Antibodies, Neutralizing</subject><subject>Antibodies, Viral</subject><subject>Antigens</subject><subject>BNT162 Vaccine</subject><subject>CD4 antigen</subject><subject>ChAdOx1 nCoV-19</subject><subject>Comparative analysis</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Demographics</subject><subject>Disease transmission</subject><subject>Heterologous vaccination</subject><subject>Homology</subject><subject>Humans</subject><subject>Hybrid immunity</subject><subject>IgG antibody</subject><subject>Immunization</subject><subject>Immunoassay</subject><subject>Immunoglobulin G</subject><subject>Immunologic Memory</subject><subject>Immunological memory</subject><subject>Infections</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Medical personnel</subject><subject>Memory cells</subject><subject>Neutralizing</subject><subject>Neutralizing antibody</subject><subject>Observational studies</subject><subject>Peptides</subject><subject>Plasma</subject><subject>Priming</subject><subject>Prospective Studies</subject><subject>Proteins</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>T cell</subject><subject>T-Lymphocytes - immunology</subject><subject>Tumor necrosis factor-TNF</subject><subject>Vaccination</subject><subject>Vaccine</subject><subject>γ-Interferon</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFUk2P0zAQjRCILQs_AWSJCwdS_JnEF1BZPqUVXIqEuFixM2ldJfau7VQqf4k_iaN2K-DCxbbGb97Mm3lF8ZTgJcGkerVb7ltjrIMlxZQtMVniit0rFqSpWUkFae4XC0wrXnKCv18Uj2LcYYwFI_JhccGqWvC64ovi1wptIUHwg9_4KaLVj3eEUopugh2t26DWdejtlzWpqKZIex_THA2wsSM4NPoACPreGgsuDQcEQ36miBxMKbSD_XnkSFb7zkJ8ifSUkPMJjZBzD2iNDAxDjqdt6_IBaOvHu17OdU_lHhcP-naI8OR0XxbfPrxfX30qr79-_Hy1ui4NlyKV1BAhcC-bRkjdYc06zqDpqSREVzUB4Fq0AIJXmjFGuOl4YxphSN-TStQNuyxeH3lvJj1CZ7K0rEXNI2nDQfnWqr9_nN2qjd8rKTERTGaCFyeC4G8niEmNNs5CWwdZmKJ1zRspJOYZ-vwf6M5PwWV5GdVgjgWRLKPEEWWCjzFAf26GYDXbQe3UyQ5qtoPCRGU75Lxnfyo5Z93tPwPeHAGQ57m3EFScV2mgswFMUp23_ynxG_Cyyms</recordid><startdate>20230303</startdate><enddate>20230303</enddate><creator>Baek, Yae Jee</creator><creator>Kim, Woo-Joong</creator><creator>Ko, Jae-Hoon</creator><creator>Lee, Youn-Jung</creator><creator>Ahn, Jin Young</creator><creator>Kim, Jung Ho</creator><creator>Jang, Ho Cheol</creator><creator>Jeong, Hye Won</creator><creator>Kim, Yong Chan</creator><creator>Park, Yoon Soo</creator><creator>Kim, Sung-Han</creator><creator>Peck, Kyong Ran</creator><creator>Shin, Eui-Cheol</creator><creator>Choi, Jun Yong</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2490-2485</orcidid><orcidid>https://orcid.org/0000-0002-6308-9503</orcidid><orcidid>https://orcid.org/0000-0002-9490-6609</orcidid></search><sort><creationdate>20230303</creationdate><title>A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen</title><author>Baek, Yae Jee ; Kim, Woo-Joong ; Ko, Jae-Hoon ; Lee, Youn-Jung ; Ahn, Jin Young ; Kim, Jung Ho ; Jang, Ho Cheol ; Jeong, Hye Won ; Kim, Yong Chan ; Park, Yoon Soo ; Kim, Sung-Han ; Peck, Kyong Ran ; Shin, Eui-Cheol ; Choi, Jun Yong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c495t-2c1550f98859bd0b3d43e8f2911b671ee4b5aee546b33314cd48c85c1ff165783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Age</topic><topic>Antibodies</topic><topic>Antibodies, Neutralizing</topic><topic>Antibodies, Viral</topic><topic>Antigens</topic><topic>BNT162 Vaccine</topic><topic>CD4 antigen</topic><topic>ChAdOx1 nCoV-19</topic><topic>Comparative analysis</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Demographics</topic><topic>Disease transmission</topic><topic>Heterologous vaccination</topic><topic>Homology</topic><topic>Humans</topic><topic>Hybrid immunity</topic><topic>IgG antibody</topic><topic>Immunization</topic><topic>Immunoassay</topic><topic>Immunoglobulin G</topic><topic>Immunologic Memory</topic><topic>Immunological memory</topic><topic>Infections</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Medical personnel</topic><topic>Memory cells</topic><topic>Neutralizing</topic><topic>Neutralizing antibody</topic><topic>Observational studies</topic><topic>Peptides</topic><topic>Plasma</topic><topic>Priming</topic><topic>Prospective Studies</topic><topic>Proteins</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>T cell</topic><topic>T-Lymphocytes - immunology</topic><topic>Tumor necrosis factor-TNF</topic><topic>Vaccination</topic><topic>Vaccine</topic><topic>γ-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baek, Yae Jee</creatorcontrib><creatorcontrib>Kim, Woo-Joong</creatorcontrib><creatorcontrib>Ko, Jae-Hoon</creatorcontrib><creatorcontrib>Lee, Youn-Jung</creatorcontrib><creatorcontrib>Ahn, Jin Young</creatorcontrib><creatorcontrib>Kim, Jung Ho</creatorcontrib><creatorcontrib>Jang, Ho Cheol</creatorcontrib><creatorcontrib>Jeong, Hye Won</creatorcontrib><creatorcontrib>Kim, Yong Chan</creatorcontrib><creatorcontrib>Park, Yoon Soo</creatorcontrib><creatorcontrib>Kim, Sung-Han</creatorcontrib><creatorcontrib>Peck, Kyong Ran</creatorcontrib><creatorcontrib>Shin, Eui-Cheol</creatorcontrib><creatorcontrib>Choi, Jun Yong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baek, Yae Jee</au><au>Kim, Woo-Joong</au><au>Ko, Jae-Hoon</au><au>Lee, Youn-Jung</au><au>Ahn, Jin Young</au><au>Kim, Jung Ho</au><au>Jang, Ho Cheol</au><au>Jeong, Hye Won</au><au>Kim, Yong Chan</au><au>Park, Yoon Soo</au><au>Kim, Sung-Han</au><au>Peck, Kyong Ran</au><au>Shin, Eui-Cheol</au><au>Choi, Jun Yong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2023-03-03</date><risdate>2023</risdate><volume>41</volume><issue>10</issue><spage>1694</spage><epage>1702</epage><pages>1694-1702</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Comparative analyses of SARS-CoV-2-specific immune responses elicited by diverse prime-boost regimens are required to establish efficient regimens for the control of COVID-19.
In this prospective observational cohort study, spike-specific immunoglobulin G (IgG) and neutralizing antibodies (nAbs) alongside spike-specific T-cell responses in age-matched groups of homologous BNT162b2/BNT162b2 or AZD1222/AZD1222 vaccination, heterologous AZD1222/BNT162b2 vaccination, and prior wild-type SARS-CoV-2 infection/vaccination were evaluated.
Peak immune responses were achieved after the second vaccine dose in the naïve vaccinated groups and after the first dose in the prior infection/vaccination group. Peak titers of anti-spike IgG and nAb were significantly higher in the AZD1222/BNT162b2 vaccination and prior infection/vaccination groups than in the BNT162b2/BNT162b2 or AZD1222/AZD1222 groups. However, the frequency of interferon-γ-producing CD4+ T cells was highest in the BNT162b2/BNT162b2 vaccination group. Similar results were observed in the analysis of polyfunctional T cells. When nAb and CD4+T-cell responses against the Delta variant were analyzed, the prior infection/vaccination group exhibited higher responses than the groups of other homologous or heterologous vaccination regimens.
nAbs are efficiently elicited by heterologous AZD1222/BNT162b2 vaccination, as well as prior infection/vaccination, whereas spike-specific CD4+T-cell responses are efficiently elicited by homologous BNT162b2 vaccination. Variant-recognizing immunity is more efficiently generated by prior infection/vaccination than the other homologous or heterologous vaccination regimens.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>36754764</pmid><doi>10.1016/j.vaccine.2023.01.063</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-2490-2485</orcidid><orcidid>https://orcid.org/0000-0002-6308-9503</orcidid><orcidid>https://orcid.org/0000-0002-9490-6609</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2023-03, Vol.41 (10), p.1694-1702 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9901539 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Age Antibodies Antibodies, Neutralizing Antibodies, Viral Antigens BNT162 Vaccine CD4 antigen ChAdOx1 nCoV-19 Comparative analysis Coronaviruses COVID-19 COVID-19 vaccines Demographics Disease transmission Heterologous vaccination Homology Humans Hybrid immunity IgG antibody Immunization Immunoassay Immunoglobulin G Immunologic Memory Immunological memory Infections Lymphocytes Lymphocytes T Medical personnel Memory cells Neutralizing Neutralizing antibody Observational studies Peptides Plasma Priming Prospective Studies Proteins SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 T cell T-Lymphocytes - immunology Tumor necrosis factor-TNF Vaccination Vaccine γ-Interferon |
| title | A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T07%3A46%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20heterologous%20AZD1222%20priming%20and%20BNT162b2%20boosting%20regimen%20more%20efficiently%20elicits%20neutralizing%20antibodies,%20but%20not%20memory%20T%20cells,%20than%20the%20homologous%20BNT162b2%20regimen&rft.jtitle=Vaccine&rft.au=Baek,%20Yae%20Jee&rft.date=2023-03-03&rft.volume=41&rft.issue=10&rft.spage=1694&rft.epage=1702&rft.pages=1694-1702&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2023.01.063&rft_dat=%3Cproquest_pubme%3E2780405193%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2780405193&rft_id=info:pmid/36754764&rft_els_id=S0264410X23000944&rfr_iscdi=true |